Disposition and Metabolism of Safinamide, a Novel Drug for Parkinson's Disease, in Healthy Male Volunteers
Pharmacology2013Vol. 92(3-4), pp. 207–216
Citations Over TimeTop 13% of 2013 papers
Abstract
Maximum concentration was achieved at 1 h (plasma, median Tmax) for parent drug and at 7 and 1.5 h for plasma and whole blood (14)C radioactivity, respectively. Terminal half-lives were about 22 h for unchanged safinamide and 80 h for radioactivity. Safinamide deaminated acid and the N-dealkylated acid were identified as major metabolites in urine and plasma. In urine, the β-glucuronide of the N-dealkylated acid and the monohydroxy safinamide were also characterized. In addition, the glycine conjugate of the N-dealkylated acid and 2-[4-hydroxybenzylamino]propanamide were tentatively identified as minor urinary metabolites.
Related Papers
- → Effect of piperine on the bioavailability and pharmacokinetics of rosmarinic acid in rat plasma using UPLC-MS/MS(2017)22 cited
- → Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys(1990)48 cited
- → Excretion and metabolism of 1-nitropyrene in rats after oral or intraperitoneal administration*1(1985)18 cited
- → Evidence for the occurrence of a novel pathway of benzoic acid metabolism involving the addition of a two carbon fragment(1981)10 cited
- [Clometacin--1. Metabolism and bioavailability of clometacin and its metabolites in the rat].(1983)